GL1X · GenesisL1 explorer

Research workbench

Human soluble adenylyl cyclase in complex with the inhibitor TDI10229

Analyse Human soluble adenylyl cyclase in complex with the inhibitor TDI10229 in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7OVD
Type
protein
Length
449 residues
Chains
1
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Adenylate cyclase type 10
EC
4.6.1.1
UniProt
Q96PN6
Ligands
1S2
Pockets
7 · best druggability 0.77

Structure

x-ray diffraction · 1 distinct chain · 38% helix, 29% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AAdenylate cyclase type 10 (EC 4.6.1.1)protein44938% helix, 29% strandQ96PN6

Ligands and binding sites

  • 1S2 · 4-chloranyl-6-[1,5-dimethyl-4-(phenylmethyl)pyrazol-3-yl]pyrimidin-2-amine · ligand · chains A
  • EDO · 1,2-ethanediol · additive · 6 copies · chains A
  • ACT · Acetate ion · additive · 4 copies · chains A
  • DMS · Dimethyl sulfoxide · additive · 4 copies · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 3 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15010.770.85501S2, ACT
22300.750.8931ACT, EDO
31590.660.8630EDO
4550.490.8517empty
51590.460.7623empty

Modifications

Observed in the structure: 1 modified (artifact).

Compared structures

  • 7OVD · Human soluble adenylyl cyclase in complex with the inhibitor TDI10229 · the same entry in another collection · chain A against A, TM-score 1.00
  • Q96PN6 · AlphaFold monomer V2.0 prediction for adenylate cyclase type 10 (Q96PN6) · a predicted model of the same protein · chain A against A, TM-score 0.96

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.